Study comparing the diagnostic value of Ga-68-PSMA-PET with conventional imaging in selecting patients suitable for Ra-223-chloride therapy

Trial Profile

Study comparing the diagnostic value of Ga-68-PSMA-PET with conventional imaging in selecting patients suitable for Ra-223-chloride therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 04 Apr 2017 New trial record
    • 14 Feb 2017 Results published in the Nuklearmedizin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top